JP2016509007A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016509007A5 JP2016509007A5 JP2015556563A JP2015556563A JP2016509007A5 JP 2016509007 A5 JP2016509007 A5 JP 2016509007A5 JP 2015556563 A JP2015556563 A JP 2015556563A JP 2015556563 A JP2015556563 A JP 2015556563A JP 2016509007 A5 JP2016509007 A5 JP 2016509007A5
- Authority
- JP
- Japan
- Prior art keywords
- bone
- biospecific
- agent
- core
- contrast agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000988 bone and bone Anatomy 0.000 claims 19
- 239000003795 chemical substances by application Substances 0.000 claims 18
- 229940079593 drug Drugs 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 239000002872 contrast media Substances 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 4
- 238000002591 computed tomography Methods 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 3
- 239000000090 biomarker Substances 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 238000002595 magnetic resonance imaging Methods 0.000 claims 3
- 210000002997 osteoclast Anatomy 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 208000020084 Bone disease Diseases 0.000 claims 2
- 239000002616 MRI contrast agent Substances 0.000 claims 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims 2
- 230000000975 bioactive effect Effects 0.000 claims 2
- 239000000696 magnetic material Substances 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 229910052692 Dysprosium Inorganic materials 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 229910052688 Gadolinium Inorganic materials 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 208000029725 Metabolic bone disease Diseases 0.000 claims 1
- 206010027452 Metastases to bone Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 206010049088 Osteopenia Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 102000014128 RANK Ligand Human genes 0.000 claims 1
- 108010025832 RANK Ligand Proteins 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 239000000956 alloy Substances 0.000 claims 1
- 229910045601 alloy Inorganic materials 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000002449 bone cell Anatomy 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- -1 boro sulfate Chemical compound 0.000 claims 1
- 150000001718 carbodiimides Chemical class 0.000 claims 1
- 239000010941 cobalt Substances 0.000 claims 1
- 229910017052 cobalt Inorganic materials 0.000 claims 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 238000013170 computed tomography imaging Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000007769 metal material Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229920005615 natural polymer Polymers 0.000 claims 1
- 229910052759 nickel Inorganic materials 0.000 claims 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 210000000963 osteoblast Anatomy 0.000 claims 1
- 230000002188 osteogenic effect Effects 0.000 claims 1
- 230000000010 osteolytic effect Effects 0.000 claims 1
- 210000004663 osteoprogenitor cell Anatomy 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims 1
- 108010091748 peptide A Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 229940014800 succinic anhydride Drugs 0.000 claims 1
- 229920001059 synthetic polymer Polymers 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1302199.3A GB2510587B (en) | 2013-02-07 | 2013-02-07 | Biospecific agents for bone |
| GB1302199.3 | 2013-02-07 | ||
| PCT/GB2014/050265 WO2014122431A1 (en) | 2013-02-07 | 2014-01-31 | Biospecific agents for bone |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018153482A Division JP6683773B2 (ja) | 2013-02-07 | 2018-08-17 | 骨のための生体特異的な薬剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016509007A JP2016509007A (ja) | 2016-03-24 |
| JP2016509007A5 true JP2016509007A5 (enExample) | 2017-02-23 |
| JP6400026B2 JP6400026B2 (ja) | 2018-10-03 |
Family
ID=47998779
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015556563A Active JP6400026B2 (ja) | 2013-02-07 | 2014-01-31 | 骨のための生体特異的な薬剤 |
| JP2018153482A Active JP6683773B2 (ja) | 2013-02-07 | 2018-08-17 | 骨のための生体特異的な薬剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018153482A Active JP6683773B2 (ja) | 2013-02-07 | 2018-08-17 | 骨のための生体特異的な薬剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20150367000A1 (enExample) |
| EP (1) | EP2953682B1 (enExample) |
| JP (2) | JP6400026B2 (enExample) |
| CN (1) | CN105142729A (enExample) |
| CA (1) | CA2898366C (enExample) |
| ES (1) | ES2904260T3 (enExample) |
| GB (1) | GB2510587B (enExample) |
| NZ (1) | NZ710436A (enExample) |
| WO (1) | WO2014122431A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3226905T3 (pl) | 2014-02-27 | 2022-04-19 | Synartro Ab | Koniugaty kwasu hialuronowego z farmaceutycznie aktywnymi substancjami, sposoby i kompozycje |
| JP7156665B2 (ja) * | 2017-06-13 | 2022-10-19 | 国立研究開発法人量子科学技術研究開発機構 | 医薬、並びにその製造方法 |
| CN108187143A (zh) * | 2018-02-09 | 2018-06-22 | 福州大学 | 一种兼具磁热效应和原位诱导成骨的多功能复合材料及其制备方法 |
| CN109289119B (zh) * | 2018-09-16 | 2022-05-17 | 华北理工大学 | 一种用于脊柱康复系统的磁性纳米粒子球混合物 |
| US11944982B2 (en) | 2019-06-05 | 2024-04-02 | Battelle Memorial Institute | Polymer-functionalized magnetic particle embodiments for solute separation, and devices and systems for using the same |
| CN111558041A (zh) * | 2020-04-30 | 2020-08-21 | 浙江理工大学 | 羟基磷灰石包裹磁性载药纳米颗粒及其制备方法和在制备骨肉瘤光疗药物中的应用 |
| WO2023041639A2 (fr) * | 2021-09-15 | 2023-03-23 | Centre National De La Recherche Scientifique | Nanoparticules hybrides |
| CN117582485B (zh) * | 2023-11-15 | 2024-06-07 | 湛江中心人民医院 | 方格星虫三肽在制备骨质疏松药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH694935A5 (de) * | 2000-07-26 | 2005-09-30 | Straumann Holding Ag | Oberflaechenmodifizierte Implantate. |
| WO2003072593A2 (en) * | 2002-02-21 | 2003-09-04 | University Of Virginia Patent Foundation | Bone targeting peptides |
| CA2554755A1 (en) * | 2004-01-28 | 2005-08-11 | Cytimmune Sciences, Inc. | Functionalized colloidal metal compositions and methods |
| CN101155549B (zh) * | 2005-03-21 | 2011-11-16 | 加利福尼亚大学董事会 | 官能化磁性纳米颗粒及其使用方法 |
| AU2012204100B2 (en) * | 2005-03-21 | 2014-03-06 | The Regents Of The University Of California | Functionalized magnetic nanoparticles and methods of use thereof |
| ES2574810T3 (es) * | 2005-09-28 | 2016-06-22 | The Regents Of The University Of California | Péptidos de unión a calcio |
| US20100028387A1 (en) * | 2007-06-12 | 2010-02-04 | Ganesan Balasundaram | Biocompatible Coated Nanostructured Titanium Surfaces |
| US8063636B2 (en) * | 2009-05-29 | 2011-11-22 | The Invention Science Fund I, Llc | Systems, devices, methods, and compositions including targeted ferromagnetic structures |
| US9316645B2 (en) * | 2011-10-07 | 2016-04-19 | Brown University | Methods, compositions and kits for imaging cells and tissues using nanoparticles and spatial frequency heterodyne imaging |
-
2013
- 2013-02-07 GB GB1302199.3A patent/GB2510587B/en not_active Expired - Fee Related
-
2014
- 2014-01-31 WO PCT/GB2014/050265 patent/WO2014122431A1/en not_active Ceased
- 2014-01-31 CN CN201480007874.8A patent/CN105142729A/zh active Pending
- 2014-01-31 US US14/765,508 patent/US20150367000A1/en not_active Abandoned
- 2014-01-31 EP EP14702931.8A patent/EP2953682B1/en active Active
- 2014-01-31 CA CA2898366A patent/CA2898366C/en active Active
- 2014-01-31 NZ NZ710436A patent/NZ710436A/en not_active IP Right Cessation
- 2014-01-31 ES ES14702931T patent/ES2904260T3/es active Active
- 2014-01-31 JP JP2015556563A patent/JP6400026B2/ja active Active
-
2018
- 2018-08-17 JP JP2018153482A patent/JP6683773B2/ja active Active
-
2019
- 2019-11-25 US US16/693,780 patent/US11464878B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016509007A5 (enExample) | ||
| Pucci et al. | Superparamagnetic iron oxide nanoparticles for magnetic hyperthermia: Recent advancements, molecular effects, and future directions in the omics era | |
| Estelrich et al. | Iron oxide nanoparticles for magnetically-guided and magnetically-responsive drug delivery | |
| US9376690B2 (en) | Templated nanoconjugates | |
| Arsianti et al. | Assembly of polyethylenimine-based magnetic iron oxide vectors: insights into gene delivery | |
| Chen et al. | Increasing the efficacy of stem cell therapy via triple-function inorganic nanoparticles | |
| Javed et al. | Cofibrillization of pathogenic and functional amyloid proteins with gold nanoparticles against amyloidogenesis | |
| Qadir et al. | Non-viral delivery system and targeted bone disease therapy | |
| Zhang et al. | Smart bacterial magnetic nanoparticles for tumor-targeting magnetic resonance imaging of HER2-positive breast cancers | |
| Samal et al. | Multilayered magnetic gelatin membrane scaffolds | |
| Gonçalves et al. | Magnetic responsive cell-based strategies for diagnostics and therapeutics | |
| Eftekhari et al. | The potential application of magnetic nanoparticles for liver fibrosis theranostics | |
| Zhao et al. | Electrical-charge-mediated cancer cell targeting via protein corona-decorated superparamagnetic nanoparticles in a simulated physiological environment | |
| JP2018534932A (ja) | 条件的活性型ポリペプチド | |
| Sun et al. | Targeting and regulating of an oncogene via nanovector delivery of MicroRNA using patient-derived xenografts | |
| Sizikov et al. | Nonviral locally injected magnetic vectors for in vivo gene delivery: A review of studies on magnetofection | |
| JP2008536907A (ja) | 遺伝子送達 | |
| Gao et al. | Magnetic nanoparticles for biomedical applications: From diagnosis to treatment to regeneration | |
| Tang et al. | Nanoparticles as a novel platform for cardiovascular disease diagnosis and therapy | |
| Zară-Dănceanu et al. | Magnetic nanoparticle coating decreases the senescence and increases the targeting potential of fibroblasts and adipose-derived mesenchymal stem cells | |
| US20220160906A1 (en) | Compositions of and methods of making ferritin-based imaging agents | |
| WO2019028469A1 (en) | FUNCTIONALIZED POLYMER MITOCHONDRIAL COMPOSITIONS AND METHODS OF USE IN CELL TRANSPLANTATION AND FOR MODIFYING METABOLIC PHENOTYPE | |
| WO2019191650A1 (en) | Compositions and methods for targeting cells | |
| KR102336120B1 (ko) | 금 나노입자-앱타머 결합체를 기반으로 하는 항체 전달체 및 이의 제조 방법 | |
| Li et al. | Non-invasive Diagnosis and Postoperative Evaluation of Carotid Artery Stenosis by BSA-Gd2O3 Nanoparticles-Based Magnetic Resonance Angiography |